Reata Pharmaceuticals (NASDAQ:RETA) Given New $245.00 Price Target at Robert W. Baird
Reata Pharmaceuticals (NASDAQ:RETA) had its price target hoisted by Robert W. Baird from $162.00 to $245.00 in a research report released on Tuesday, The Fly reports. Robert W. Baird currently has a positive rating on the stock.
Other research analysts also recently issued research reports about the company. Cantor Fitzgerald boosted their price target on Reata Pharmaceuticals from $180.00 to $250.00 and gave the company an overweight rating in a research note on Monday, November 4th. Stifel Nicolaus boosted their price target on Reata Pharmaceuticals from $135.00 to $210.00 and gave the company a buy rating in a research note on Wednesday, October 16th. LADENBURG THALM/SH SH reaffirmed a positive rating and issued a $239.00 price target (up previously from $133.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, October 16th. ValuEngine raised Reata Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, November 1st. Finally, Leerink Swann set a $230.00 price target on Reata Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $247.63.
Shares of NASDAQ RETA traded down $4.53 during midday trading on Tuesday, reaching $198.91. The company’s stock had a trading volume of 877,400 shares, compared to its average volume of 645,809. The stock has a 50 day simple moving average of $152.87 and a 200-day simple moving average of $102.51. The stock has a market capitalization of $5.64 billion, a price-to-earnings ratio of -69.31 and a beta of 2.75. Reata Pharmaceuticals has a fifty-two week low of $47.50 and a fifty-two week high of $217.47.
In other Reata Pharmaceuticals news, VP Jason Douglas Wilson sold 10,000 shares of the business’s stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $170.00, for a total transaction of $1,700,000.00. Following the completion of the transaction, the vice president now owns 17,350 shares of the company’s stock, valued at $2,949,500. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Elaine Castellanos sold 4,000 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $200.00, for a total value of $800,000.00. Following the transaction, the chief accounting officer now directly owns 19,146 shares of the company’s stock, valued at approximately $3,829,200. The disclosure for this sale can be found here. In the last ninety days, insiders sold 101,000 shares of company stock valued at $10,661,430. 34.40% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Resources Investment Advisors LLC. acquired a new position in Reata Pharmaceuticals during the second quarter worth about $25,000. Meadow Creek Investment Management LLC raised its stake in Reata Pharmaceuticals by 71.4% during the second quarter. Meadow Creek Investment Management LLC now owns 336 shares of the company’s stock worth $32,000 after acquiring an additional 140 shares in the last quarter. Lindbrook Capital LLC acquired a new position in Reata Pharmaceuticals during the third quarter worth about $32,000. Glen Harbor Capital Management LLC raised its stake in Reata Pharmaceuticals by 71.4% during the second quarter. Glen Harbor Capital Management LLC now owns 408 shares of the company’s stock worth $39,000 after acquiring an additional 170 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Reata Pharmaceuticals by 1,603.1% during the third quarter. Tower Research Capital LLC TRC now owns 545 shares of the company’s stock worth $44,000 after acquiring an additional 513 shares in the last quarter. 58.24% of the stock is owned by hedge funds and other institutional investors.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.